The size of the Asia Pacific Ovarian Cancer Therapeutics Market is estimated to be growing at a healthy CAGR from 2020 to 2025.
Ovarian cancer occurs when cell growth in the ovarian tissue becomes uncontrollable. Ovarian cancer is one of the most common causes of death in women across the world. The most common type of cancer among women is ovarian cancer. The treatment of ovarian cancer is done depending on the stage the disease is in. The treatment includes surgery, radiation, chemotherapy, and biological therapy. It is also known that ovarian cancer is the most chemo-sensitive cancer. Chemotherapy treatment is more effective when combined with radiation therapy. Hence, the market for ovarian cancer therapeutics has a great potential.
One of the factors is increase in aging of the women population. Introduction of new drugs and effective therapies, increase in people’s disposable income, and better government funding and support are some of the key factors behind the growth of global ovarian cancer market. Additionally, increasing awareness about healthcare is also propelling the growth of the ovarian cancer market. Recent launches of generic drugs, and expiration of patents of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin are some of the key factors restraining the growth for ovarian cancer market.
The ovarian cancer market is segmented based on the stage of cancer as Stage I, Stage II, Stage III and Stage IV. Stages of cancer are further sub-segmented into Stage IA, Stage IB, Stage IC, Stage IIA, Stage IIB, Stage IIC, Stage IIIA, Stage IIIB and Stage IIIC. By cancer type, it is segmented into Primary Peritoneal Carcinoma, Ovarian Stromal Tumors, Ovarian Germ Cell Tumors and Epithelial Ovarian Tumors. By Diagnosis, it is further segmented into Physical Examination, Blood Tests, Ultrasound, PET, CT Scan, MRI, Human Chorionic Gonadotropin Test and Biopsy, By type of treatment, it is segmented into Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery, Immunotherapy and Targeted Therapy. Futhermore, based on geography the market is segmented into various regions namely Japan, China, India and Australia. Latin America and Middle East and Africa regions are still behind in this field. However, Asia-Pacific is expected to be the fastest growing regional market. Large-scale R&D is being done in the region which support the growth of Asia-Pacific market.
Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Genentech Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Stage Of Cancer
5.1.1 Stage I
5.1.1.1 Stage IA
5.1.1.2 Stage IB
5.1.1.3 Stage IC
5.1.2 Stage II
5.1.2.1 Stage IIA
5.1.2.2 Stage IIB
5.1.2.3 Stage IIC
5.1.3 Stage III
5.1.3.1 Stage IIIA
5.1.3.2 Stage IIIB
5.1.3.3 Stage IIIC
5.1.4 Stage IV
5.1.5 Y-o-Y Growth Analysis, By Stage Of Cancer
5.1.6 Market Attractiveness Analysis, By Stage Of Cancer
5.1.7 Market Share Analysis, By Stage Of Cancer
5.2 Type
5.2.1 Introduction
5.2.2 Primary Peritoneal Carcinoma
5.2.3 Ovarian Stromal Tumors
5.2.4 Ovarian Germ Cell Tumors
5.2.5 Epithelial Ovarian Tumors
5.2.6 Y-o-Y Growth Analysis, By Type
5.2.7 Market Attractiveness Analysis, By Type
5.2.8 Market Share Analysis, By Type
5.3 Diagnosis
5.3.1 Introduction
5.3.2 Physical Examination
5.3.3 Blood Tests
5.3.4 Ultrasound
5.3.5 PET
5.3.6 CT Scan
5.3.7 MRI
5.3.8 Human Chorionic Gonadotropin Test
5.3.9 Biopsy
5.3.10 Y-o-Y Growth Analysis, By Diagnosis
5.3.11 Market Attractiveness Analysis, By Diagnosis
5.3.12 Market Share Analysis, By Diagnosis
5.4 Treatment
5.4.1 Introduction
5.4.2 Chemotherapy
5.4.3 Radiation Therapy
5.4.4 Hormonal Therapy
5.4.5 Surgery
5.4.6 Immunotherapy
5.4.7 Targeted Therapy
5.4.8 Y-o-Y Growth Analysis, By Treatment
5.4.9 Market Attractiveness Analysis, By Treatment
5.4.10 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Stage of Cancer
6.1.3.3 By Type
6.1.3.4 By Diagnosis
6.1.3.5 By Treatment
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.3.2 By Stage of Cancer
6.1.3.3 By Type
6.1.3.4 By Diagnosis
6.1.3.5 By Treatment
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.3.2 By Stage of Cancer
6.1.3.3 By Type
6.1.3.4 By Diagnosis
6.1.3.5 By Treatment
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Aetera Zenteris Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Eli Lilly and Company
8.3 Roche
8.4 Amgen
8.5 Janssen Pharmaceuticals, Inc.
8.6 Bristol Myers Squibb Company
8.7 Novogen, Inc.
8.8 GlaxoSmithKline
8.9 Boehringer Ingelheim
8.10 AstraZeneca
8.11 Genentech Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
